Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy

Objective: We employed diffusion-weighted magnetic resonance spectroscopy (DW-MRS), which allows to measure in vivo the diffusion properties of metabolites, to explore the functional neuro-axonal damage and the ongoing energetic dysregulation in multiple sclerosis (MS). Methods: Twenty-five patients with MS and 18 healthy controls (HC) underwent conventional magnetic resonance imaging (MRI) and DW-MRS. The apparent diffusion coefficient (ADC) of total N-acetyl-aspartate (tNAA) and creatine–phosphocreatine (tCr) were measured in the parietal normal-appearing white matter (NAWM) and in the thalamic grey matter (TGM). Multiple regressions were used to compare metabolite ADCs between groups and to explore clinical correlations. Results: In patients compared with HCs, we found a reduction in ADC(tNAA) in the TGM, reflecting functional and structural neuro-axonal damage, and in ADC(tCr) in both NAWM and TGM, possibly reflecting a reduction in energy supply in neurons and glial cells. Metabolite ADCs did not correlate with tissue atrophy, lesional volume or metabolite concentrations, while in TGM metabolite ADCs correlated with clinical scores. Conclusion: DW-MRS showed a reduction in tCr diffusivity in the normal-appearing brain of patients with MS, which might reflect a state of ongoing energy dysregulation affecting neurons and/or glial cells. Reversing this energy dysregulation before neuro-axonal degeneration arises may become a key objective in future neuroprotective strategies.

[1]  M. Simons,et al.  A unified cell biological perspective on axon–myelin injury , 2014, The Journal of cell biology.

[2]  F. Jacques Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[3]  Julien Valette,et al.  Diffusion‐Weighted Magnetic Resonance Spectroscopy , 2015 .

[4]  David H. Miller,et al.  Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes , 2010, Journal of magnetic resonance imaging : JMRI.

[5]  Arjan Hillebrand,et al.  Functional brain networks: Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG Study , 2015, Human brain mapping.

[6]  D. Mahad,et al.  Mitochondrial changes associated with demyelination: consequences for axonal integrity. , 2012, Mitochondrion.

[7]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[8]  K. Nave Myelination and support of axonal integrity by glia , 2010, Nature.

[9]  Peter M. G. Munro,et al.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. , 1996, Neuroreport.

[10]  Itamar Ronen,et al.  Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. , 2016, Brain : a journal of neurology.

[11]  Mary T. Brinkoetter,et al.  A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis , 2011, Nature Medicine.

[12]  À. Rovira,et al.  1H magnetic resonance spectroscopy in multiple sclerosis and related disorders. , 2013, Neuroimaging clinics of North America.

[13]  David H. Miller,et al.  Assessing Neuronal Metabolism In Vivo by Modeling Imaging Measures , 2010, The Journal of Neuroscience.

[14]  Y. G. Graaf,et al.  What drives MRI-measured cortical atrophy in multiple sclerosis? , 2015, Multiple sclerosis.

[15]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[16]  Olivier Braissant,et al.  Synthesis and transport of creatine in the CNS: importance for cerebral functions , 2010, Journal of neurochemistry.

[17]  Peter K. Stys,et al.  Will the real multiple sclerosis please stand up? , 2012, Nature Reviews Neuroscience.

[18]  Peter K Stys,et al.  Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.

[19]  K. Nicolay,et al.  Diffusion NMR spectroscopy , 2001, NMR in biomedicine.

[20]  G. Cioni,et al.  A novel mouse model of creatine transporter deficiency , 2014, F1000Research.

[21]  Masahiko Watanabe,et al.  Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK‐Mi and CK‐B suggest a novel neuron–glial relationship for brain energy homeostasis , 2004, The European journal of neuroscience.

[22]  Itamar Ronen,et al.  Functional diffusion‐weighted magnetic resonance spectroscopy of the human primary visual cortex at 7 T , 2013, Magnetic resonance in medicine.

[23]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[24]  S. Provencher Automatic quantitation of localized in vivo 1H spectra with LCModel , 2001, NMR in biomedicine.

[25]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.

[26]  J. Hoogduin,et al.  Reduced Creatine Kinase B Activity in Multiple Sclerosis Normal Appearing White Matter , 2010, PloS one.

[27]  Peter K. Stys,et al.  General mechanisms of axonal damage and its prevention , 2005, Journal of the Neurological Sciences.

[28]  Peter B Barker,et al.  Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy , 2012, The Journal of Neuroscience.